DIAGNOS Announces Grant of Stock Options
March 04 2024 - 3:45PM
Diagnos Inc. ("DIAGNOS" or the "Corporation") (TSX Venture: ADK)
(OTCQB: DGNOF), a pioneer in early detection of critical health
issues through the use of Artificial Intelligence (AI)
technologies, announces a grant of 250,000 stock options to one of
its directors, Mr. Michael Braeuel, in connection with his
appointment to the Corporation’s board of directors announced by
way of news release on February 29, 2024.
Stock options vest at 50% per year, commencing
with the first anniversary of the grant. The exercise price of the
stock options has been established at $0.28 per common share. The
date of the grant is March 4, 2024. The expiry date to which the
stock options can be exercised is March 4, 2029.
All monies quoted in this press release shall be
stated and paid in lawful money of Canada.
About DIAGNOSDIAGNOS is a publicly traded
Canadian corporation dedicated to early detection of critical
health problems based on its FLAIRE Artificial Intelligence (AI)
platform. FLAIRE allows for quick modifying and developing of
applications such as CARA (Computer Assisted Retina Analysis).
CARA’s image enhancement algorithms provide sharper, clearer and
easier-to-analyze retinal images. CARA is a cost-effective tool for
real-time screening of large volumes of patients.
Additional information is available at
www.diagnos.com and www.sedar.com.
This news release contains forward-looking
information. There can be no assurance that forward-looking
information will prove to be accurate, as actual results and future
events could differ materially from those anticipated in these
statements. DIAGNOS disclaims any intention or obligation to
publicly update or revise any forward-looking information, whether
as a result of new information, future events or otherwise. The
forward-looking information contained in this news release is
expressly qualified by this cautionary statement.
Neither the TSX Venture Exchange nor its
Regulation Services Provider (as that term is defined in the
policies of the TSX Venture Exchange) accepts responsibility for
the adequacy or accuracy of this release.
For further information, please contact:
Mr. André Larente, President
DIAGNOS Inc.
Tel: 450-678-8882 ext. 224
alarente@diagnos.ca
Diagnos (TSXV:ADK)
Historical Stock Chart
From Jun 2024 to Jul 2024
Diagnos (TSXV:ADK)
Historical Stock Chart
From Jul 2023 to Jul 2024